NMDSG-14B2
Key facts
- Where
- Goteborg, Huddinge, Linkoping, Lund, Umeå és Uppsala, SvédországSee the 6 sites
- Phase
- 2. fázis
Where in Svédország
- Sahlgrenska University Hospital-Vaestra GoetalandsregionenGoteborg, SvédországTaking people
- Karolinska University HospitalHuddinge, SvédországTaking people
- Linkoping University Hospital Region OstergotlandLinkoping, SvédországTaking people
- Region Skane Skanes UniversitetssjukhusLund, SvédországTaking people
- Norrlands University HospitalUmeå, SvédországTaking people
- Uppsala University HospitalUppsala, SvédországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Karolinska University Hospital
- Trial code
- EU 2024-511651-17-00
- Record updated
- 2026. május 27.
- Original description
To prevent clinical events (relapse or non-relapse death) in minimal residual disease (MRD) positive subjectsRead full original descriptionShow less
A phase II multicenter single-armed study using subject-specific minimal residual minimal disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myleodysplastic syndrome - MDS
To prevent clinical events (relapse or non-relapse death) in minimal residual disease (MRD) positive subjects
Inclusion: Signed informed consent; Age ≥ 18 years; Subjects eligible for stem cell transplantation; Subjects having the disease myelodysplastic syndrome (MDS), mixed myelodysplastic/myeloproliferative syndrome or acute myeloid leukemia (AML) with myelodysplasia related dysplasia and 20-29% marrow blasts; All female subjects of childbearing potential have to have negative pregnancy test within 2 weeks prior to inclusion to the study.
Exclusion: Uncontrolled hypertension, heart, liver, kidney related or other uncontrolled medical or psychiatric disorders; No traceable genetic aberration identified either in screening next generation sequencing panel or next generation sequencing panel performed at diagnosis; Mental inability, reluctance or language difficulties that results in difficulty understanding the meaning of study participation.